

# Are you dealing with crusty, itchy, red eyelids?

**xdemvy**<sup>®</sup>  
(lotilaner ophthalmic solution) 0.25%

If so, it's time to speak to your eye doctor.

**Demodex blepharitis**—also known as DB—is an eyelid disease caused by an infestation of *Demodex* mites, which are a common mite found on humans.<sup>1,2</sup> It's estimated that approximately 25 million eye care patients in the US are affected by DB.<sup>3,4</sup>



## Prepare to discuss your symptoms.

Bring this completed checklist to your next eye doctor appointment.

Responses are not a diagnosis.



→ **Over the past month, which signs and symptoms have you experienced?**<sup>1-3,5</sup>  
(Check all that apply.)

- Eyelid redness
- Crusties (collarettes) on eyelashes
- Eyelid irritation
- Missing or misdirected eyelashes
- Eyelid itching
- Eyelid swelling

→ **How are you currently managing your symptoms?**  
(Check all that apply.)

- Eyelid cleanser
- Eyelid wipes
- Eyelid foams
- In-office eyelid treatments
- Warm compresses
- Baby shampoo
- Other \_\_\_\_\_

→ **How would you describe your current symptom management plan?**  
(Check all that apply.)

- Cumbersome
- Difficult to adhere to
- Not managing my symptoms
- Working OK but could be better
- Working OK
- Other \_\_\_\_\_

→ **Have your symptoms made it harder to do any of these daily activities?**  
(Check all that apply.)

- School/office work
- Family or social gatherings
- Taking vacations or travel
- Wearing makeup
- Difficulty driving at night
- Daily hygiene routine
- Other \_\_\_\_\_

→ **When do your symptoms occur most often?**  
(Select the option that best fits you.)

- First thing in the morning
- During the day
- At night/when trying to sleep

→ **How often do you visit an eye doctor?**  
(Select one.)

- Multiple times a year
- Once a year
- I have never seen an eye doctor
- Only when I am having issues with my eyes

### Indications and Usage

XDEMZY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of *Demodex* blepharitis.

### Important Safety Information

**Most common side effects:** The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see additional Important Safety Information on next page and full [Prescribing Information](#) attached.

# Ready to break up your mite party? XDEMVY<sup>®</sup> can help.

**xdemvy**<sup>®</sup>  
(lotilaner ophthalmic solution) 0.25%

Your eye doctor can prescribe XDEMVY, the **only FDA-approved eye drop treatment** that targets and kills the *Demodex* mites that cause DB.<sup>6</sup>

→ **One drop per eye, twice a day, approximately 12 hours apart, in just 6 weeks**

In 2 combined studies, 50% of patients had a reduction of crusties (collarettes) and 60% of patients had their *Demodex* mites completely wiped out<sup>7\*</sup>

→ **Designed for comfort**

~90% of patients in 2 combined studies reported XDEMVY eye drops as neutral to very comfortable to use<sup>7†</sup>

→ **Stay on top of your treatment**

It's important to use XDEMVY for the full 6 weeks

→ **Reduce eyelid redness**

Patients using XDEMVY for DB may see eyelid redness gone in just 6 weeks<sup>6</sup>

→ **Maintain eyelid health**

Over time, mites may come back, so it's important to see your eye doctor regularly. If signs and symptoms such as eyelid redness, itching, or crusties (collarettes) return, make an appointment to visit your eye doctor right away so they can check for DB<sup>1,3,5</sup>

→ **Tarsus Connect**

Tarsus is committed to making XDEMVY affordable and accessible.

**Insurance coverage of XDEMVY continues to expand, reaching an average of over 85% of insured patients across Commercial, Medicare Part D, and Medicaid.** The majority of patients pay \$30 or less<sup>‡</sup>

- Please ask your pharmacist how you can save on XDEMVY
- The pharmacy may require personal information like your social security number to evaluate your eligibility for financial assistance



Real patient with DB used XDEMVY twice daily, in each eye, for 6 weeks. Results may vary.



If you think you might have DB, scan the QR code to find an eye doctor near you!

\*XDEMVY for *Demodex* blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVY).<sup>6,8,9</sup>

**Trial 1:** When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (n=209) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 68% of patients (n=212) at Day 43.

**Trial 2:** When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (n=193) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 50% of patients (n=203) at Day 43.

† All visits averaged.<sup>7</sup>

‡ With payer coverage and available assistance options, and based on eligibility requirements; see XDEMVY Savings and Access [Terms and Conditions](#).

## Important Safety Information (Cont'd)

**Handling the Container:** Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

**When to Seek Physician Advice:** Immediately seek a physician's advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

**Use with Contact Lenses:** XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see full [Prescribing Information](#) attached.

By prescription only.

**References:** 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. *Demodex* blepharitis: clinical perspectives. *Clin Optim (Auckl)*. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. *Demodex* blepharitis: a comprehensive review of the disease, current management, and emerging therapies. *Eye Contact Lens*. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of *Demodex* blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. *Clin Ophthalmol*. 2022;16:1153-1164. 4. O'Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of *Demodex* blepharitis. *Clin Ophthalmol*. 2022;16:2979-2987. 5. Sędzikowska A, Osęka M, Grytner-Zięcina B. Ocular symptoms reported by patients infested with *Demodex* mites. *Acta Parasitol*. 2016;61(4):808-814. 6. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals Inc; 2023. 7. Yeu E, Paauw JD, Vollmer P, et al. Safety and efficacy of lotilaner ophthalmic solution (0.25%) in treating *Demodex* blepharitis: pooled analysis of two pivotal trials. *Ophthalmol Ther*. 2025;14(3):555-571. 8. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for *Demodex* blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). *Ophthalmology*. 2023;130(10):1015-1023. 9. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of *Demodex* blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). *Cornea*. 2023;42(4):435-443.



©2026 Tarsus Pharmaceuticals, Inc. All rights reserved.  
XDEMVY, TARSUS, certain other trademarks, and any associated logo(s) herein are trademarks owned exclusively by Tarsus Pharmaceuticals, Inc.  
US--2600002 3/26